U.S. patent court rejects Alvogen's challenge for Celgene's Revlimid
March 14, 2019 at 09:09 AM EDT
A U.S. administrative court on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp's blockbuster myeloma drug Revlimid.
